Our study on prostate cancer also supports regulation by methylation as treatment of PC-3, LNCaP, and DU145 with demethylating agent caused an enhanced increase of CYP1A1 expression with dramatic loss of methylation as shown by MSP/USP analyses of the enhancer XRE-1383 site. This evidence concerns the gene CYP1A1 and prostate carcinoma.